The Ocugen Inc (NASDAQ:OCGN) stock has emerged as one of the biggest gainers in the market after it announced its partnership with Indian firm Bharat Biotech for the COVID 19 vaccine Covaxin.
The company is going to collaborate on the development of the vaccine and also distribute it in the United States. However, the question remains whether the stock can really sustain the gains it has clocked so far. A closer look at the deal raises several pertinent questions.
Ocugen only owns the licensing rights for Covaxin for the United States market and on top of that, its success is going to depend on how quickly it can commercialize the product. In addition to that, the market for coronavirus vaccine is possibly brimming with options at the moment and it remains to be seen if Covaxin can corner any market share once it gets the approval. Despite the gains, the jury might still be out on whether the company can actually capitalize on this break in a big way.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life